<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791360</url>
  </required_header>
  <id_info>
    <org_study_id>TCSEQ</org_study_id>
    <nct_id>NCT02791360</nct_id>
  </id_info>
  <brief_title>Evaluation of Anatomy, Clinical and Neuropsychological Long-term Sequelae of Patients Treated With Radiation Therapy for Brain Tumor</brief_title>
  <acronym>TCSEQ</acronym>
  <official_title>Evaluation of Anatomy, Clinical and Neuropsychological Long-term Sequelae of Patients Treated With Radiation Therapy for Brain Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through this study, the investigators believe to describe more accurately the damage caused&#xD;
      by brain radiation therapy in the long term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patient with MRI abnormality</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>To evaluate the proportion of patients with at least one abnormality on an imaging test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI diffusion abnormality</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI perfusion abnormality</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI vascular morphologic abnormalities</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>MRI evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient pretreated for brain tumor and witness</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <arm_group_label>MRI evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In the case group:&#xD;
&#xD;
          -  A history of solid brain tumor or haematological histologically proven.&#xD;
&#xD;
          -  Patients previously treated with radiotherapy in this brain tumor (greater than or&#xD;
             equal to 36 Gy dose).&#xD;
&#xD;
          -  Radiotherapy treatment on a tumor in place or operated.&#xD;
&#xD;
          -  Decline at least 10 years from the end of radiotherapy.&#xD;
&#xD;
          -  Treatment with isocentric conformal radiotherapy.&#xD;
&#xD;
          -  No other radiation therapy for locally recurrent brain metastases or new brain tumor.&#xD;
&#xD;
          -  Lack of known brain metastases or meningeal carcinomatosis.&#xD;
&#xD;
        For the control group:&#xD;
&#xD;
          -  Patients previously treated for cancer and disease relapse free for 10 years.&#xD;
&#xD;
          -  No brain radiotherapy treatment.&#xD;
&#xD;
          -  Lack of treatment with anti-cancer chemotherapy.&#xD;
&#xD;
          -  Women of childbearing potential must be under effective contraception.&#xD;
&#xD;
          -  Pairing according to age, sex, arms director and socio-cultural level.&#xD;
&#xD;
        For two groups:&#xD;
&#xD;
          -  Man or woman aged (e) of minimum 18 years.&#xD;
&#xD;
          -  Topic fluent French and comprising well.&#xD;
&#xD;
          -  Free and Informed Consent signed.&#xD;
&#xD;
          -  The subject should be affiliated to an appropriate social security system&#xD;
&#xD;
          -  No cons-indication to MRI.&#xD;
&#xD;
          -  The subject must have at least one primary school level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In the case group:&#xD;
&#xD;
          -  Brain radiotherapy carried out by intensity modulation technique.&#xD;
&#xD;
          -  Radiation dose less than 36 Gy on the brain.&#xD;
&#xD;
          -  Subject with against-indication to MRI.&#xD;
&#xD;
        For the control group:&#xD;
&#xD;
          -  Previous history of brain radiotherapy.&#xD;
&#xD;
          -  Previous history of brain surgery.&#xD;
&#xD;
          -  Central neurological disorders, such as seizures, uncontrolled.&#xD;
&#xD;
        For two groups:&#xD;
&#xD;
          -  Current Topics in oral chemotherapy or intravenous.&#xD;
&#xD;
          -  Subject pregnant.&#xD;
&#xD;
          -  Subject is not fluent in French or including bad.&#xD;
&#xD;
          -  Any geographical conditions, social or associated psychopathology that could&#xD;
             compromise the patient's ability to participate in the study.&#xD;
&#xD;
          -  Participation in a therapeutic trial for less than 30 days.&#xD;
&#xD;
          -  A person not affiliated with a social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>MRI</keyword>
  <keyword>Sequelae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

